Humana Inc. (NYSE:HUM) Shares Acquired by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ boosted its holdings in Humana Inc. (NYSE:HUM) by 7.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,787 shares of the insurance provider’s stock after purchasing an additional 1,690 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Humana were worth $6,823,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Revolve Wealth Partners LLC purchased a new position in shares of Humana in the 4th quarter valued at approximately $202,000. American Century Companies Inc. lifted its holdings in shares of Humana by 8.8% during the fourth quarter. American Century Companies Inc. now owns 12,655 shares of the insurance provider’s stock worth $3,211,000 after purchasing an additional 1,027 shares during the period. UniSuper Management Pty Ltd grew its position in Humana by 32.8% in the 4th quarter. UniSuper Management Pty Ltd now owns 11,227 shares of the insurance provider’s stock valued at $2,848,000 after buying an additional 2,770 shares during the last quarter. NEOS Investment Management LLC increased its stake in Humana by 27.9% in the 4th quarter. NEOS Investment Management LLC now owns 5,697 shares of the insurance provider’s stock valued at $1,445,000 after buying an additional 1,241 shares during the period. Finally, New Age Alpha Advisors LLC purchased a new position in Humana during the 4th quarter worth $2,960,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HUM has been the topic of several analyst reports. Barclays set a $268.00 target price on shares of Humana and gave the company an “equal weight” rating in a report on Thursday, June 12th. Wall Street Zen raised Humana from a “hold” rating to a “buy” rating in a report on Sunday, July 20th. Oppenheimer lifted their price target on Humana from $300.00 to $310.00 and gave the company an “outperform” rating in a research note on Thursday, May 1st. Cantor Fitzgerald reiterated a “neutral” rating and issued a $290.00 price objective on shares of Humana in a research report on Thursday, May 1st. Finally, Robert W. Baird reduced their target price on Humana from $300.00 to $297.00 and set a “neutral” rating for the company in a report on Friday. Sixteen equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Humana presently has an average rating of “Hold” and a consensus price target of $282.43.

Humana Price Performance

HUM stock opened at $238.22 on Monday. The stock’s 50 day moving average price is $234.56 and its 200 day moving average price is $256.11. The firm has a market cap of $28.75 billion, a P/E ratio of 16.85, a PEG ratio of 1.63 and a beta of 0.44. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.91 and a current ratio of 1.91. Humana Inc. has a 1 year low of $206.87 and a 1 year high of $406.09.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.07 by $1.51. The business had revenue of $32.11 billion for the quarter, compared to the consensus estimate of $32 billion. Humana had a return on equity of 14.47% and a net margin of 1.42%. The business’s revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the business earned $7.23 earnings per share. On average, sell-side analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.